QRG Capital Management Cuts Stake in Merck Amid Bullish Sentiment
QRG Capital Management Inc., an institutional investor, trimmed its stake in Merck & Co., Inc. (NYSE:MRK) by 14.2% during the second quarter. The company's holdings in Merck were worth $55,126,000 at the end of the most recent quarter.
Merck has been a focus for investors due to its pipeline of clinical readouts over the next 12-18 months. Bank of America maintained its Buy rating on Merck after meetings with the company's chief medical officer. The analyst cited multiple potential oncology and other clinical readouts, which could drive a re-rating of the stock.
Additionally, Merck received positive news when the FDA approved updated labeling for WINREVAIR, incorporating Phase 3 HYPERION data for recently diagnosed adults with pulmonary arterial hypertension. This expansion broadens the therapy's supported clinical use and may strengthen WINREVAIR's contribution to Merck's growth.
Despite this positive sentiment, analysts note that Merck's valuation is high at 118 times earnings. The stock has substantially outperformed the broader market over the past year, prompting concerns that the rally has outpaced near-term fundamentals.